Multiple Myeloma Articles | Page 2

Wave of Therapies Being Developed in AL Amyloidosis Space
Sandy W. Wong, MD, discusses immunoglobulin light chain amyloidosissome and recent data that have shown excitement in this landscape.
CAR T-Cell Therapy an Emerging Explosion in Myeloma Paradigm
Nina Shah, MD, discusses immunotherapy and cellular treatments moving fast through the multiple myeloma pipeline, and the hope for CAR T-cell therapy to move up to earlier lines of treatment.
FDA Grants Priority Review to Frontline Daratumumab for Multiple Myeloma
The FDA has granted a priority review designation to daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
FDA Approves Carfilzomib Label Update in Myeloma
The FDA has approved a supplemental new drug application that adds overall survival data from the phase III ENDEAVOR trial to the label for carfilzomib for use in patients with relapsed or refractory multiple myeloma.
Emerging Therapies Generate Excitement in Myeloma
Thomas G. Martin, MD, discusses emerging advancements in the treatment landscape of multiple myeloma.
FDA Approves Denosumab for Multiple Myeloma
The FDA has approved denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.
Daratumumab Regimen Maintains Favorable Performance in Relapsed/Refractory Myeloma
Progression-free survival remained superior over time in patients with relapsed/refractory multiple myeloma treated treated with combination therapy that included the anti-CD38 antibody daratumumab (Darzalex).
NICE Recommends Ixazomib for Multiple Myeloma Through CDF
The United Kingdom's National Institute for Health and Care Excellence has issued guidance recommending ixazomib in for patients with relapsed/refractory multiple myeloma.
Selinexor Combo Highly Active in Relapsed/Refractory Myeloma
Selinexor combined with weekly bortezomib and low-dose dexamethasone produced rapid and durable responses in a dose escalation/expansion trial of patients with relapsed/refractory multiple myeloma.
New Analysis Confirms Carfilzomib Survival Benefit in Relapsed/Refractory Myeloma
The addition of carfilzomib to lenalidomide and dexamethasone for relapsed/refractory multiple myeloma led to a statistically significant 21% reduction in the risk for death compared with lenalidomide and dexamethasone.
Publication Bottom Border
Border Publication